Sage Therapeutics Inc (FRA:SG7)
€ 5.452 0.102 (1.91%) Market Cap: 325.18 Mil Enterprise Value: -211.07 Mil PE Ratio: 0 PB Ratio: 0.61 GF Score: 49/100

Q4 2018 SAGE Therapeutics Inc Earnings Call Transcript

Feb 19, 2019 / 01:00PM GMT
Release Date Price: €135.38 (-3.45%)
Operator

Good morning, and welcome to Sage Therapeutics Fourth Quarter 2018 Financial Results Conference Call. (Operator Instructions) This call is being webcast live on the Investors & Media section of Sage's website at sagerx.com.

This call is the property of Sage Therapeutics, and recording, reproduction or transmission of this call without the express written consent of Sage Therapeutics is strictly prohibited. Please note that this call is being recorded.

I would now like to introduce Paul Cox, Investor Relations at Sage.

Paul Cox
Sage Therapeutics, Inc. - Senior Director of IR

Good morning. Today, we issued a press release with our fourth quarter and full year 2018 financial results, along with recent company highlights, upcoming milestones and progress on our corporate strategy. The press release referenced on this call can be found on the Investors & Media section of our website at sagerx.com.

We will begin the call with prepared remarks by Dr. Jeff Jonas, Chief Executive Officer; Mike Cloonan, Chief Business Officer; and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot